AvePoint AVPT 深 沪
等待开盘 09-23 09:30:00 美东时间
13.10
-0.260
-1.95%
华盛通- 最 高13.56
- 今 开13.52
- 成交量 133.54万股
- 最 低 12.84
- 昨 收 13.36
- 总市值 27.72亿
- 52周最高 15.58
- 市盈率 静 86.30
- 换手率 0.63%
- 52周最低 8.835
- 委 比 -70.34%
- 总股本 2.12亿
- 历史最高 20.245
- 量 比 0.61
- 振 幅 5.39%
- 历史最低 3.40
- 每 手 1
- 风险率 1.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 麦当劳目标价遭下调至320美元！现价仍有近3成上涨空间；戴尔、迈威尔、微软齐获机构看好
今日重点评级关注：HC Wainwright & Co.：维持Gossamer Bio"买入"评级，目标价从2美元升至90美元；巴克莱：维持Ultragenyx Pharmaceutical"超配"评级，目标价从32美元升至35美元
09-22 16:25
Stephens & Co. Maintains Overweight on AvePoint, Raises Price Target to $17
Stephens & Co. analyst Todd Weller maintains AvePoint (NASDAQ:AVPT) with a Overweight and raises the price target from $16 to $17.
09-21 20:33
Zoom appoints Jeff Epstein to Board of Directors
Zoom (ZM) said on Wednesday it appointed former Oracle CFO Jeff Epstein to its Board, effective immediately, succeeding Jonathan Chadwick. Epstein currently serves on the boards of Autodesk, AvePoint,...
09-03 05:12
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Evercore ISI Group Maintains Outperform on AvePoint, Raises Price Target to $16
Evercore ISI Group analyst Kirk Materne maintains AvePoint (NASDAQ:AVPT) with a Outperform and raises the price target from $14 to $16.
08-07 20:29
财报速睇 | AvePoint, Inc. Class A 2026财年Q2营收1.24亿美元，同比增长22.0%；归母净利润0.28亿美元，同比增长921.9%
华盛资讯8月7日讯，AvePoint, Inc. Class A公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长22.0%，归母净利润0.28亿美元，同比增长921.9%。
08-07 11:37
财报速睇 | AvePoint, Inc. Class A 2026财年Q2营收1.24亿美元，同比增长22.0%；归母净利润0.28亿美元，同比增长921.9%
华盛资讯8月7日讯，AvePoint, Inc. Class A公布2026财年Q2业绩，公司Q2营收1.24亿美元，同比增长22.0%，归母净利润0.28亿美元，同比增长921.9%。
08-07 07:31
AvePoint Lowers FY2026 Sales Guidance from $509.400M-$517.400M to $508.500M-$512.500M vs $512.730M Est
AvePoint (NASDAQ:AVPT) lowers FY2026 sales outlook from $509.400 million-$517.400 million to $508.500 million-$512.500 million vs $512.730 million estimate.
08-07 04:27
AvePoint Sees Q3 Sales $128.200M-$130.200M vs $133.613M Est
AvePoint (NASDAQ:AVPT) sees Q3 sales of $128.200 million-$130.200 million vs $133.613 million analyst estimate.
08-07 04:27
AvePoint Q2 EPS $0.12 Beats $0.04 Estimate, Sales $124.495M Beat $121.367M Estimate
AvePoint (NASDAQ:AVPT) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.04 by 200 percent. This is a 1100 percent increase over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $124.495 million which bea...
08-07 04:14
